Novel approaches to modulate apoptosis resistance: Basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL)

Current Drug Delivery

Volumn 9, Issue 1, 2012, Pages 30-40

  Masood, Aisha ^a   Shahshahan, Mohammad A ^b   Jazirehi, Ali R ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Signaling; Targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; ATM PROTEIN; BENDAMUSTINE; BIOLOGICAL MARKER; CAL 101; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOKINE RECEPTOR; FLAVOPIRIDOL; FLUDARABINE; FOSTAMATINIB; ISOSORBIDE; LENALIDOMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NAVITOCLAX; OBATOCLAX; OBINUTUZUMAB; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN MDM2; RADIXIN; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATAXIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONFUSION; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DNA DAMAGE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; EUPHORIA; FATIGUE; GENE MUTATION; HUMAN; ILEUS; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 83455236831     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112798376050     Document Type: Review

References (119)

1. Lowe, S. W.; Lin, A. W. Apoptosis in cancer. Carcinogenesis, 2000, 21 (3), 485-495.
2. Bellosillo, B.; Dalmau, M.; Colomer, D.; Gil, J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood, 1997, 89 (9), 3378-3384.
3. Reed, J. C.; Kitada, S.; Kim, Y.; Byrd, J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin. Oncol., 2002, 29 (1 Suppl 2), 10-24.
4. Wang, J.; Lenardo, M. J. Molecules involved in cell death and peripheral tolerance. Curr. Opin. Immunol., 1997, 9 (6), 818-825.
5. Green, D. R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000, 102 (1), 1-4.
6. Green, D. R.; Bissonnette, R. P.; Glynn, J. M.; Shi, Y. Activationinduced apoptosis in lymphoid systems. Semin. Immunol., 1992, 4 (6), 379-388.
7. Wang, D.; Freeman, G. J.; Levine, H.; Ritz, J.; Robertson, M. J. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol., 1997, 97 (2), 409-417.
8. Ghia, P.; Boussiotis, V. A.; Schultze, J. L.; Cardoso, A. A.; Dorfman, D. M.; Gribben, J. G.; Freedman, A. S.; Nadler, L. M. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood, 1998, 91(1), 244-251.
9. Banchereau, J.; Bazan, F.; Blanchard, D.; Briere, F.; Galizzi, J. P.; van Kooten, C.; Liu, Y. J.; Rousset, F.; Saeland, S. The CD40 antigen and its ligand. Annu. Rev. Immunol., 1994, 12, 881-922.
10. Kitada, S.; Andersen, J.; Akar, S.; Zapata, J. M.; Takayama, S.; Krajewski, S.; Wang, H. G.; Zhang, X.; Bullrich, F.; Croce, C. M.; Rai, K.; Hines, J.; Reed, J.C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood, 1998, 91(9), 3379-3389.
11. Kitada, S.; Pedersen, I. M.; Schimmer, A. D.; Reed, J. C. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene, 2002, 21(21), 3459-3474.
12. Kitada, S.; Zapata, J. M.; Andreeff, M.; Reed, J. C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 1999, 106(4), 995-1004.
13. Granziero, L.; Ghia, P.; Circosta, P.; Gottardi, D.; Strola, G.; Geuna, M.; Montagna, L.; Piccoli, P.; Chilosi, M.; Caligaris-Cappio, F. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood, 2001, 97(9), 2777-2783.
14. von Bergwelt-Baildon, M.; Maecker, B.; Schultze, J.; Gribben, J. G. CD40 activation: potential for specific immunotherapy in BCLL. Ann. Oncol., 2004, 15 (6), 853-857.
15. Buggins, A. G.; Pepper, C. J. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk. Res., 2010, 34 (7), 837-842.
16. Ghia, P.; Strola, G.; Granziero, L.; Geuna, M.; Guida, G.; Sallusto, F.; Ruffing, N.; Montagna, L.; Piccoli, P.; Chilosi, M.; Caligaris-Cappio, F. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol., 2002, 32(5), 1403-1413.
17. Tai, Y. T.; Podar, K.; Mitsiades, N.; Lin, B.; Mitsiades, C.; Gupta, D.; Akiyama, M.; Catley, L.; Hideshima, T.; Munshi, N. C.; Treon, S. P.; Anderson, K. C. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood, 2003, 101(7), 2762-2769.
18. Packham, G.; Stevenson, F. K. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology, 2005, 114(4), 441-449.
19. Herr, I.; Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood, 2001, 98(9), 2603-2614.
20. Reed, J. C. Apoptosis-based therapies. Nat. Rev. Drug Discov., 2002, 1(2), 111-121.
21. Byrd, J. C.; Kitada, S.; Flinn, I. W.; Aron, J. L.; Pearson, M.; Lucas, D.; Reed, J. C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 2002, 99(3), 1038-1043.
22. Schimmer, A. D.; Munk-Pedersen, I.; Minden, M. D.; Reed, J. C. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr. Treat Opt. Oncol., 2003, 4(3), 211-218.
23. Cimmino, A.; Calin, G. A.; Fabbri, M.; Iorio, M. V.; Ferracin, M.; Shimizu, M.; Wojcik, S. E.; Aqeilan, R. I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C. G.; Kipps, T. J.; Negrini, M.; Croce, C. M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA, 2005, 102(39), 13944-13949.
24. Caligaris-Cappio, F. Role of the microenvironment in chronic lymphocytic leukaemia. Br. J. Haematol., 2003, 123(3), 380-388.
25. Michels, J.; O'Neill, J. W.; Dallman, C. L.; Mouzakiti, A.; Habens, F.; Brimmell, M.; Zhang, K. Y.; Craig, R. W.; Marcusson, E. G.; Johnson, P. W.; Packham, G. Mcl-1 is required for Akata6 Blymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene, 2004, 23(28), 4818-4827.
26. Deaglio, S.; Malavasi, F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica, 2009, 94(6), 752-756.
27. Cuni, S.; Perez-Aciego, P.; Perez-Chacon, G.; Vargas, J. A.; Sanchez, A.; Martin-Saavedra, F. M.; Ballester, S.; Garcia-Marco, J.; Jorda, J.; Durantez, A. A sustained activation of PI3K/NFkappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia, 2004, 18(8), 1391-1400.
28. Ahmed, N. N.; Grimes, H. L.; Bellacosa, A.; Chan, T. O.; Tsichlis, P. N. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc. Natl. Acad. Sci. USA, 1997, 94(8), 3627-3632.
29. Brennan, P.; Babbage, J. W.; Burgering, B. M.; Groner, B.; Reif, K.; Cantrell, D. A. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity, 1997, 7(5), 679-689.
30. Kashiwada, M.; Lu, P.; Rothman, P. B. PIP3 pathway in regulatory T cells and autoimmunity. Immunol. Res., 2007, 39(1-3), 194-224.
31. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science, 2002, 296 (5573), 1655-1657.
32. Stilgenbauer, S.; Bullinger, L.; Lichter, P.; Dohner, H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia, 2002, 16(6), 993-1007.
33. Byrd, J. C.; Stilgenbauer, S.; Flinn, I. W. Chronic Lymphocytic. Leuk. Hematol., 2004, 2004(1), 163-183.
34. Winkler, D.; Schneider, C.; Krober, A.; Pasqualucci, L.; Lichter, P.; Dohner, H.; Stilgenbauer, S. Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL). Leukemia, 2005, 19(7), 1211-1215.
35. Starostik, P.; Manshouri, T.; O'Brien, S.; Freireich, E.; Kantarjian, H.; Haidar, M.; Lerner, S.; Keating, M.; Albitar, M. Deficiency of the ATM protein expression defines an aggressive subgroup of Bcell chronic lymphocytic leukemia. Cancer Res., 1998, 58(20), 4552-4557.
36. Stilgenbauer, S.; Liebisch, P.; James, M. R.; Schroder, M.; Schlegelberger, B.; Fischer, K.; Bentz, M.; Lichter, P.; Dohner, H. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA, 1996, 93(21), 11837-11841.
37. Zent, C. S. Time to test CLL p53 function. Blood, 2010, 115(21), 4154-4155.
38. Sionov, R. V.; Haupt, Y. The cellular response to p53: the decision between life and death. Oncogene, 1999, 18(45), 6145-6157.
39. Sionov, R. V.; Moallem, E.; Berger, M.; Kazaz, A.; Gerlitz, O.; Ben-Neriah, Y.; Oren, M.; Haupt, Y. c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J. Biol. Chem., 1999, 274(13), 8371-8374.
40. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69(7), 1237-1245.
41. Dubs-Poterszman, M. C.; Tocque, B.; Wasylyk, B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene, 1995, 11(11), 2445-2449.
42. Bartke, T.; Siegmund, D.; Peters, N.; Reichwein, M.; Henkler, F.; Scheurich, P.; Wajant, H. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene, 2001, 20(5), 571-580.
43. Seto, E.; Usheva, A.; Zambetti, G. P.; Momand, J.; Horikoshi, N.; Weinmann, R.; Levine, A. J.; Shenk, T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 1992, 89(24), 12028-12032.
44. Hoffman, W. H.; Biade, S.; Zilfou, J. T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem., 2002, 277(5), 3247-3257.
45. Ryan, K. M.; Phillips, A. C.; Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol., 2001, 13(3), 332-337.
46. Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Busch, R.; Fingerle-Rowson, G.; Fischer, K.; Fink, A.-M.; Jager, U.; Bottcher, S.; Kneba, M.; Wenger, M.; Mendila, M.; Hallek, M.; Dohner, H. Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial. ASH Annual Meeting Abstracts 2008, 112(11), 781.
47. Dohner, H.; Fischer, K.; Bentz, M.; Hansen, K.; Benner, A.; Cabot, G.; Diehl, D.; Schlenk, R.; Coy, J.; Stilgenbauer, S.; et al., p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 1995, 85(6), 1580-1589.
48. Gonzalez-Rodriguez, A. P.; Contesti, J.; Huergo-Zapico, L.; Lopez-Soto, A.; Fernandez-Guizan, A.; Acebes-Huerta, A.; Gonzalez-Huerta, A. J.; Gonzalez, E.; Fernandez-Alvarez, C.; Gonzalez, S. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk. Lymph., 2010, 51(10), 1829-1836.
49. Hallek, M.; Cheson, B. D.; Catovsky, D.; Caligaris-Cappio, F.; Dighiero, G.; Dohner, H.; Hillmen, P.; Keating, M. J.; Montserrat, E.; Rai, K. R.; Kipps, T. J. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 2008, 111(12), 5446-55456.
50. Hallek, M.; Pflug, N. Chronic lymphocytic leukemia. Ann. Oncol., 2010, 21 (Suppl 7), vii154-vii164.
51. Cramer, P.; Hallek, M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat. Rev. Clin. Oncol., 2010, 8(1), 38-47.
52. Dohner, H.; Stilgenbauer, S.; Benner, A.; Leupolt, E.; Krober, A.; Bullinger, L.; Dohner, K.; Bentz, M.; Lichter, P. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med., 2000, 343(26), 1910-1916.
53. Rai, K. R.; Peterson, B. L.; Appelbaum, F. R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G. A.; Larson, R. A.; Cheson, B. D.; Schiffer, C. A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med., 2000, 343(24), 1750-1757.
54. Robak, T.; Blonski, J. Z.; Kasznicki, M.; Blasinska-Morawiec, M.; Krykowski, E.; Dmoszynska, A.; Mrugala-Spiewak, H.; Skotnicki, A. B.; Nowak, W.; Konopka, L.; Ceglarek, B.; Maj, S.; Dwilewicz-Trojaczek, J.; Hellmann, A.; Urasinski, I.; Zdziarska, B.; Kotlarek-Haus, S.; Potoczek, S.; Grieb, P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood, 2000, 96 (8), 2723-2729.
55. Eichhorst, B. F.; Busch, R.; Stilgenbauer, S.; Stauch, M.; Bergmann, M. A.; Ritgen, M.; Kranzhofer, N.; Rohrberg, R.; Soling, U.; Burkhard, O.; Westermann, A.; Goede, V.; Schweighofer, C. D.; Fischer, K.; Fink, A. M.; Wendtner, C. M.; Brittinger, G.; Dohner, H.; Emmerich, B.; Hallek, M. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood, 2009, 114 (16), 3382-3391.
56. Eichhorst, B. F.; Busch, R.; Hopfinger, G.; Pasold, R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jager, U.; Bergmann, M.; Stilgenbauer, S.; Schweighofer, C.; Wendtner, C. M.; Dohner, H.; Brittinger, G.; Emmerich, B.; Hallek, M. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2006, 107(3), 885-891.
57. Flinn, I. W.; Neuberg, D. S.; Grever, M. R.; Dewald, G. W.; Bennett, J. M.; Paietta, E. M.; Hussein, M. A.; Appelbaum, F. R.; Larson, R. A.; Moore, D. F., Jr.; Tallman, M. S. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol., 2007, 25(7), 793-798.
58. Stilgenbauer, S.; Eichhorst, B. F.; Busch, R.; Zenz, T.; Winkler, D.; Buhler, A.; Goede, V.; Wendtner, C. M.; Lichter, P.; Emmerich, B.; Hallek, M.; Dohner, H. Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG. ASH Annual Meeting Abstracts 2008, 112(11), 2089.
59. Knauf, W. U.; Lissichkov, T.; Aldaoud, A.; Liberati, A.; Loscertales, J.; Herbrecht, R.; Juliusson, G.; Postner, G.; Gercheva, L.; Goranov, S.; Becker, M.; Fricke, H. J.; Huguet, F.; Del Giudice, I.; Klein, P.; Tremmel, L.; Merkle, K.; Montillo, M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2009, 27(26), 4378-4384.
60. Huhn, D.; von Schilling, C.; Wilhelm, M.; Ho, A. D.; Hallek, M.; Kuse, R.; Knauf, W.; Riedel, U.; Hinke, A.; Srock, S.; Serke, S.; Peschel, C.; Emmerich, B. Rituximab therapy of patients with Bcell chronic lymphocytic leukemia. Blood, 2001, 98(5), 1326-1331.
61. O'Brien, S. M.; Kantarjian, H.; Thomas, D. A.; Giles, F. J.; Freireich, E. J.; Cortes, J.; Lerner, S.; Keating, M. J. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol., 2001, 19(8), 2165-2170.
62. Schulz, H.; Klein, S. K.; Rehwald, U.; Reiser, M.; Hinke, A.; Knauf, W. U.; Aulitzky, W. E.; Hensel, M.; Herold, M.; Huhn, D.; Hallek, M.; Diehl, V.; Engert, A. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood, 2002, 100(9), 3115-3120.
63. Byrd, J. C.; Rai, K.; Peterson, B. L.; Appelbaum, F. R.; Morrison, V. A.; Kolitz, J. E.; Shepherd, L.; Hines, J. D.; Schiffer, C. A.; Larson, R. A. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood, 2005, 105(1), 49-53.
64. Woyach, J. A.; Ruppert, A. S.; Heerema, N. A.; Peterson, B.; Gribben, J. G.; Morrison, V. A.; Rai, K. R.; Larson, R. A.; Byrd, J. C. Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. ASH Annual Meeting Abstracts 2009, 114 (22), 539.
65. Tam, C. S.; O'Brien, S.; Wierda, W.; Kantarjian, H.; Wen, S.; Do, K. A.; Thomas, D. A.; Cortes, J.; Lerner, S.; Keating, M. J. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 2008, 112(4), 975-980.
66. Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Grunhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P. L.; Caligaris-Cappio, F.; Seymour, J. F.; Berrebi, A.; Jager, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.; Staib, P.; Buhler, A.; Winkler, D.; Zenz, T.; Bottcher, S.; Ritgen, M.; Mendila, M.; Kneba, M.; Dohner, H.; Stilgenbauer, S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 2010, 376(9747), 1164-1174.
67. Fischer, K.; Cramer, P.; Stilgenbauer, S.; Busch, R.; Balleisen, L.; Kilp, J.; Fink, A.-M.; Boettcher, S.; Ritgen, M.; Kneba, M.; Staib, P.; Dohner, H.; Schulte, S.; Eichhorst, B. F.; Hallek, M.; Wendtner, C.-M.; the German CLL Study Group Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 2009, 114(22), 205.
68. Hillmen, P.; Skotnicki, A. B.; Robak, T.; Jaksic, B.; Dmoszynska, A.; Wu, J.; Sirard, C.; Mayer, J., Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25(35), 5616-5623.
69. Stilgenbauer, S.; Dohner, H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med., 2002, 347(6), 452-453.
70. Wierda, W.; O'Brien, S.; Wen, S.; Faderl, S.; Garcia-Manero, G.; Thomas, D.; Do, K. A.; Cortes, J.; Koller, C.; Beran, M.; Ferrajoli, A.; Giles, F.; Lerner, S.; Albitar, M.; Kantarjian, H.; Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23(18), 4070-4078.
71. Keating, M. J.; Flinn, I.; Jain, V.; Binet, J. L.; Hillmen, P.; Byrd, J.; Albitar, M.; Brettman, L.; Santabarbara, P.; Wacker, B.; Rai, K. R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 2002, 99(10), 3554-3561.
72. Wierda, W. G.; Kipps, T. J.; Mayer, J.; Stilgenbauer, S.; Williams, C. D.; Hellmann, A.; Robak, T.; Furman, R. R.; Hillmen, P.; Trneny, M.; Dyer, M. J.; Padmanabhan, S.; Piotrowska, M.; Kozak, T.; Chan, G.; Davis, R.; Losic, N.; Wilms, J.; Russell, C. A.; Osterborg, A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2010, 28 (10), 1749-55.
73. Chanan-Khan, A.; Miller, K. C.; Musial, L.; Lawrence, D.; Padmanabhan, S.; Takeshita, K.; Porter, C. W.; Goodrich, D. W.; Bernstein, Z. P.; Wallace, P.; Spaner, D.; Mohr, A.; Byrne, C.; Hernandez-Ilizaliturri, F.; Chrystal, C.; Starostik, P.; Czuczman, M. S. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol., 2006, 24 (34), 5343-5349.
74. Ferrajoli, A.; Lee, B. N.; Schlette, E. J.; O'Brien, S. M.; Gao, H.; Wen, S.; Wierda, W. G.; Estrov, Z.; Faderl, S.; Cohen, E. N.; Li, C.; Reuben, J. M.; Keating, M. J. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 2008, 111(11), 5291-5297.
75. Sorror, M. L.; Storer, B. E.; Sandmaier, B. M.; Maris, M.; Shizuru, J.; Maziarz, R.; Agura, E.; Chauncey, T. R.; Pulsipher, M. A.; McSweeney, P. A.; Wade, J. C.; Bruno, B.; Langston, A.; Radich, J.; Niederwieser, D.; Blume, K. G.; Storb, R.; Maloney, D. G. Fiveyear follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J. Clin. Oncol., 2008, 26 (30), 4912-4920.
76. Stolz, C.; Hess, G.; Hahnel, P. S.; Grabellus, F.; Hoffarth, S.; Schmid, K. W.; Schuler, M., Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood, 2008, 112(8), 3312-3321.
77. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A. B.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Gribben, J.; Itri, L. M.; Rai, K. R. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol., 2009, 27(31), 5208-5212.
78. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Bociek, R. G.; Pavletic, S.; Rai, K. R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25(9), 1114-1120.
79. Moore, J. O.; Boyd, T. E.; Chanan-Khan, A. A.; O'Brien, S. Durable Clinical Benefit Is Associated with Objective Response and Not Lack of Progression in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results from the Genasense/Flu/Cy Phase 3 Study. ASH Annual Meeting Abstracts 2006, 108(11), 2828.
80. Chanan-Khan, A. A.; Mavromatis, B.; Rai, K. R.; Casey, P.; Novick, S.; Itri, L. M. A Pilot Study of Genasense(R) (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2004, 104(11), 4827.
81. Chanan-Khan, A. A.; Niesvizky, R.; Hohl, R. J.; Zimmerman, T. M.; Christiansen, N. P.; Schiller, G. J.; Callander, N.; Lister, J.; Oken, M.; Jagannath, S. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk. Lymph., 2009, 50(4), 559-565.
82. Rai, K. R.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Golenkov, A. K.; Koziner, B.; Chanan-Khan, A.; Bociek, R. G.; Itri, L. M. Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2004, 104(11), 338.
83. O'Brien, S. M.; Cunningham, C. C.; Golenkov, A. K.; Turkina, A. G.; Novick, S. C.; Rai, K. R., Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23(30), 7697-7702.
84. Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju, S. R.; Goulet, D.; Viallet, J.; Belec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R. W.; Beauparlant, P.; Shore, G. C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA, 2007, 104(49), 19512-19517.
85. O'Brien, S. M.; Claxton, D. F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M. J.; Viallet, J.; Cheson, B. D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood, 2009, 113(2), 299-305.
86. Borthakur, G.; O'Brien, S.; Ravandi-Kashani, F.; Giles, F.; Schimmer, A. D.; Viallet, J.; Kantarjian, H. A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2006, 108 (11), 2654.
87. Schimmer, A. D.; Brandwein, J.; O'Brien, S. M.; Kantarjian, H.; Cheson, B. D.; Minden, M. D.; Yee, K.; Schuh, A.; Gupta, V.; Viallet, J.; Borthakur, G. A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies. ASH Annual Meeting Abstracts 2007, 110 (11), 892.
88. Schimmer, A. D.; O'Brien, S.; Kantarjian, H.; Brandwein, J.; Cheson, B. D.; Minden, M. D.; Yee, K.; Ravandi, F.; Giles, F.; Schuh, A.; Gupta, V.; Andreeff, M.; Koller, C.; Chang, H.; Kamel-Reid, S.; Berger, M.; Viallet, J.; Borthakur, G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res., 2008, 14(24), 8295-8301.
89. Castro, J. E.; Loria, O. J.; Aguillon, R. A.; James, D.; Llanos, C. A.; Rassenti, L.; Wood, B. A.; Homlund, J. T.; Kipps, T. J. A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens. ASH Annual Meeting Abstracts 2007, 110 (11), 3119.
90. Castro, J. E.; Olivier, L. J.; Robier, A. A.; Danelle, J.; Carlos, S. J.; Bi-Ying, Y.; Thomas, K. J. A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2006, 108 (11), 2838.
91. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10(5), 389-399.
92. Roberts, A. W.; Brown, J.; Seymour, J. F.; Wierda, W. G.; Kipps, T. J.; Xiong, H.; Chiu, Y.-L.; Busman, T.; Knight, R. A.; Enschede, S.; Krivoshik, A.; Humerickhouse, R. An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2008, 112 (11), 3177.
93. Lock, R.; Carol, H.; Houghton, P. J.; Morton, C. L.; Kolb, E. A.; Gorlick, R.; Reynolds, C. P.; Maris, J. M.; Keir, S. T.; Wu, J.; Smith, M. A. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2008, 50(6), 1181-1189.
94. Keating, M. J.; O'Brien, S.; Albitar, M.; Lerner, S.; Plunkett, W.; Giles, F.; Andreeff, M.; Cortes, J.; Faderl, S.; Thomas, D.; Koller, C.; Wierda, W.; Detry, M. A.; Lynn, A.; Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23(18), 4079-4088.
95. Hallek, M.; Fingerle-Rowson, G.; Fink, A.-M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Gruenhagen, U.; Bergmann, M. A.; Catalano, J.; Zinzani, P. L.; Cappio, F. C.; Seymour, J. F.; Berrebi, A.; Jaeger, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C.-M.; Eichhorst, B. F.; Staib, P.; Boettcher, S.; Ritgen, M.; Stilgenbauer, S.; Mendila, M.; Kneba, M.; Dohner, H.; Fischer, K. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2008, 112 (11), 325.
96. Wierda, W. G.; Kipps, T. J.; Mayer, J.; Robak, T.; Dyer, M. J.; Furman, R. R.; Hillmen, P.; Stilgenbauer, S.; Williams, C. D.; Trneny, M.; Cartron, G.; Hernandez-Ilizaliturri, F. J.; Padmanabhan, S.; Chan, G. W.; Gupta, I. V.; Gorczyca, M. M.; Davis, R. L.; Losic, N.; Lisby, S.; Osterborg, A. Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood, 2010, 116 (21), 921.
97. Morschhauser, F.; Leonard, J. P.; Fayad, L.; Coiffier, B.; Petillon, M. O.; Coleman, M.; Schuster, S. J.; Dyer, M. J.; Horne, H.; Teoh, N.; Wegener, W. A.; Goldenberg, D. M. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J. Clin. Oncol., 2009, 27(20), 3346-3353.
98. Ysebaert, L.; Laprevotte, E.; Klein, C.; Laurent, G.; Fournie, J.-J.; Quillet-Mary, A. Clinical and biological characteristics associated with in vitro activity of anti-CD20 monoclonal antibodies, Rituximab and GA101, against chronic lymphocytic leukemia cells. ASH Annual Meeting Abstracts 116 (21), 2459.
99. Chanan-Khan, A. A.; Cheson, B. D. Lenalidomide for the treatment of B-cell malignancies. J. Clin. Oncol., 2008, 26(9), 1544-1552.
100. Chanan-Khan, A. A.; Czuczman, M. S.; Padmanabhan, S.; Keating, M. J.; O'Brien, S. M.; Wierda, W. G.; Ferrajoli, A. Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients. ASH Annual Meeting Abstracts 2007, 110 (11), 3108.
101. Chanan-Khan, A.; Porter, C. W. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol., 2006, 7(6), 480-488.
102. Ferrajoli, A.; O'Brien, S. M.; Faderl, S. H.; Wierda, W. G.; Davis, D.; Lee, B.-N.; Reuben, J. M.; Schlette, E. J.; Kantarjian, H. M.; Keating, M. J. Lenalidomide Induces Complete and Partial Responses in Patients with Relapsed and Treatment-Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2006, 108 (11), 305.
103. Chen, C. I.; Paul, H.; Mariela, P.; Brandwein, J.; Kukreti, V.; Trudel, S.; Wei, E.; Tong, J.; Moran, M. A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2007, 110(11), 2042.
104. Ferrajoli, A.; O'Brien, S.; Wierda, W.; Faderl, S.; Kornblau, S.; Yerrow, K.; Estrov, Z.; Kantarjian, H.; Keating, M. Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2008, 112 (11), 45.
105. Lin, T. S.; Heerema, N. A.; Lozanski, G.; Fischer, B.; Blum, K. A.; Andritsos, L. A.; Jones, J. A.; Flynn, J. M.; Moran, M. E.; Mitchell, S.; Johnson, A. J.; Phelps, M. A.; Grever, M. R.; Byrd, J. C. Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities. ASH Annual Meeting Abstracts 2008, 112 (11), 46.
106. Ali, A.; Ghosh, A.; Nathans, R. S.; Sharova, N.; O'Brien, S.; Cao, H.; Stevenson, M.; Rana, T. M. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem., 2009, 10(12), 2072-2080.
107. Hussain, S. R.; Lucas, D. M.; Johnson, A. J.; Lin, T. S.; Bakaletz, A. P.; Dang, V. X.; Viatchenko-Karpinski, S.; Ruppert, A. S.; Byrd, J. C.; Kuppusamy, P.; Crouser, E. D.; Grever, M. R. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood, 2008, 111(6), 3190-3199.
108. Polyak, K.; Kato, J. Y.; Solomon, M. J.; Sherr, C. J.; Massague, J.; Roberts, J. M.; Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev., 1994, 8(1), 9-22.
109. Chen, R.; Keating, M. J.; Gandhi, V.; Plunkett, W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood, 2005, 106(7), 2513-2519.
110. Lanasa, M. C.; Andritsos, L.; Brown, J. R.; Gabrilove, J.; Caligaris-Cappio, F.; Larson, R.; Kipps, T. J.; Leblond, V.; Milligan, D.; Janssens, A.; Heerema, N. A.; Stilgenbauer, S.; Byrd, J. C.; Grever, M. R., Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. ASH Annual Meeting Abstracts 2010, 116 (21), 58.
111. de Frias, M.; Iglesias-Serret, D.; Cosialls, A. M.; Coll-Mulet, L.; Santidrian, A. F.; Gonzalez-Girones, D. M.; de la Banda, E.; Pons, G.; Gil, J. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica 2009, 94(12):1698-1707.
112. Stamatopoulos, B.; Meuleman, N.; De Bruyn, C.; Mineur, P.; Martiat, P.; Bron, D.; Lagneaux, L. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia, 2009, 23(12):2281-2289.
113. Fuchs, O.; Provaznikova, D.; Marinov, I.; Kuzelova, K.; Spicka, I., Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc. Hematol. Disord. Drug Targets, 2009, 9(1), 62-77.
114. Ghosh, A. K.; Kay, N. E.; Secreto, C. R.; Shanafelt, T. D. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin. Cancer Res., 2009, 15(4), 1250-1258.
115. Angelo, L. S.; Kurzrock, R., Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clin. Cancer Res., 2009, 15(4), 1123-1125.
116. Lapalombella, R.; Gowda, A.; Joshi, T.; Mehter, N.; Cheney, C.; Lehman, A.; Chen, C. S.; Johnson, A. J.; Caligiuri, M. A.; Tridandapani, S.; Muthusamy, N.; Byrd, J. C. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br. J. Haematol., 2009, 144(6), 848-855.
117. Faris, M.; Gaskin, F.; Parsons, J. T.; Fu, S. M. CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein. J. Exp. Med., 1994, 179(6), 1923-1931.
118. Furman, R. R.; Forero-Torres, A.; Shustov, A.; Drachman, J. G., A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymph., 2010, 51(2), 228-235.
119. Advani, R.; Forero-Torres, A.; Furman, R. R.; Rosenblatt, J. D.; Younes, A.; Ren, H.; Harrop, K.; Whiting, N.; Drachman, J. G. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol., 2009, 27(26), 4371-4377.